CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 76 enrolled
Drug / intervention
carboplatin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00404235
NCT00404235Phase 2Completed
CompareCT.gov

A Phase II Trial of Carboplatin (CBDCA) and ABI-007(ABX) in Patients With Unresectable Stage IV Melanoma

Alliance for Clinical Trials in Oncology·interventional·Posted Nov 28, 2006·Updated Oct 16, 2018

In Brief

A Phase 2 clinical trial evaluating carboplatin and paclitaxel albumin-stabilized nanoparticle formulation for Melanoma (Skin). Completed, enrolled 76 participants across 156 sites.

Detailed Summary

RATIONALE: Drugs used in chemotherapy, such as carboplatin and ABI-007, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects and how well giving carboplatin together with ABI-007 works in treating patients with stage IV melanoma that cannot be removed by surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma (Skin)
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 28, 2006
Enrollment StartOct 1, 2006
Primary CompletionDec 1, 2008
Study CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 19.6 years ago

Interventions

carboplatindrug

paclitaxel albumin-stabilized nanoparticle formulationdrug